
LCMS-8060
Importance of cell culture conditions in the development of therapeutic monoclonal antibody biosimilars and cell culture profiling
INDUSTRY
MOT-CLÉ
biosimilars, therapeutic monoclonal antibodies
Services / produits associés
LCMS-8060, Ensemble de méthodes LC-MS/MS pour le profilage des cultures cellulaires Ver. 3
We interviewed Dr. Shivam from Intas in India, a leading biosimilar product manufacturers in Asia having its own biopharmaceutical operations with a R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility. Shimadzu have been supporting the research and development activities undergoing at Intas.
Dr. Shivam Mukherjee
R&D Analytical Development Laboratory, Intas Pharmaceuticals Ltd.
* Les affiliés et les titres de la personne interrogée sont ceux leur appartenant au moment du reportage.
Intas Pharmaceuticals Ltd.
URL
https://www.intaspharma.com/
At Intas Biopharma unit, we focus on developing recombinant DNA and plasma derived products. We are focused on developing biosimilars of therapeutic monoclonal antibodies with the goal of "Biosimilar for Billions".
The R&D department at Intas Biopharma unit consists of several functions starting from developing clones to, screening of media followed by process design and optimization of product. At all stages the process teams are supported by a strong analytical team which focusses on characterization of the developing molecule using a variety of analytical techniques.
You can read more in the content below